Figure 4
Validation of SC-associated IncRNAs and SeCATs in MF. (A) Schematic of experimental design. The 3' ends of polyadenylated transcripts from 24 high-quality FFPE MF tumor specimens were sequenced by 3SEQ. Sequence reads were aligned to the genome and filtered by the pipeline shown. (B) Relative expression of 21 SC-associated IncRNAs and 13 SeCATs across 24 MF tumors normalized to average CD3 read count and then compared to its average expression relative to CD3 in polyclonal CD4+ T-cells from SS patients; average expression of SC-associated IncRNAs and SeCATs in SS normalized to their expression in patient-matched polyclonal CD4+ T-cells (RNA-Seq) as well as to CD3 is also shown. Gray boxes indicate no detectable expression.

Validation of SC-associated IncRNAs and SeCATs in MF. (A) Schematic of experimental design. The 3' ends of polyadenylated transcripts from 24 high-quality FFPE MF tumor specimens were sequenced by 3SEQ. Sequence reads were aligned to the genome and filtered by the pipeline shown. (B) Relative expression of 21 SC-associated IncRNAs and 13 SeCATs across 24 MF tumors normalized to average CD3 read count and then compared to its average expression relative to CD3 in polyclonal CD4+ T-cells from SS patients; average expression of SC-associated IncRNAs and SeCATs in SS normalized to their expression in patient-matched polyclonal CD4+ T-cells (RNA-Seq) as well as to CD3 is also shown. Gray boxes indicate no detectable expression.

Close Modal

or Create an Account

Close Modal
Close Modal